Injectable NSAIDs for Dogs in the UK: Metacam, Rimadyl, Onsior, Previcox & Anafen — 2025 Veterinary Treatment Guide

Metacam's meloxicam formulation is a clinic staple in the UK veterinary toolbox for rapid, reliable analgesia and anti-inflammatory control; it combines a well‑established safety record with broad clinical familiarity among practitioners. In the 2025 veterinarian guide context it ranks highly for perioperative and short‑term pain control because generics and competitive pricing often make it a cost‑effective choice versus newer, more COX‑2 selective (and usually pricier) injectables, while offering a favorable balance between efficacy and tolerability compared with agents that either have longer dosing intervals or higher GI/renal risk.

Rimadyl (carprofen) remains a market leader for postoperative and osteoarthritis pain management, prized for strong analgesic effect and predictable clinician dosing in a clinic setting. Compared with meloxicam brands in this list it often presents a similar or better price‑performance ratio for chronic musculoskeletal cases, though veterinarians consider its idiosyncratic hepatic risk profile when choosing between Rimadyl and more COX‑2 selective alternatives like robenacoxib or firocoxib.

Onsior's robenacoxib is highly COX‑2 selective and tailored for fast clinic‑administered perioperative analgesia with a favorable GI and renal safety profile in short courses, making it a top technical choice for single‑dose or short‑duration protocols. In the 2025 guide it is highlighted for its technical advantage over broader‑spectrum NSAIDs—trading a premium price for reduced adverse‑event risk and rapid onset—so clinics prioritising single‑visit procedures often prefer it to longer‑acting options like mavacoxib.

Previcox (firocoxib) delivers COX‑2 selective efficacy with a clinical profile suited to both acute perioperative use and longer‑term osteoarthritis management, offering veterinarians a reliable middle ground between short‑acting injectables and ultra‑long‑acting options. Financially and operationally it is often viewed as cost‑efficient for practices that need daily control without the monitoring concerns associated with non‑selective NSAIDs, and it competes favorably against costly long‑duration injectables when considering ongoing client costs and clinic follow‑up.

Trocoxil (mavacoxib) stands out as the long‑acting injectable in this list, offering monthly clinic‑administered dosing that drastically improves owner compliance and simplifies chronic osteoarthritis management. Although it generally carries a premium upfront cost compared with daily NSAIDs, its extended duration reduces the frequency of prescriptions and owner dosing errors—an economic and practical advantage for busy practices managing chronic cases compared with short‑acting perioperative agents.

Ketofen (ketoprofen) is a potent, non‑selective NSAID commonly used for acute inflammation and postoperative pain where strong anti‑inflammatory effect is required and short‑term dosing is planned. In the 2025 clinic context it is often chosen for its competitive price and robust anti‑inflammatory action, though vets weigh a higher GI/renal risk compared with COX‑2 selective options and typically reserve it for short courses rather than long‑term management.